J Ambrosioni1, M Hernandez-Meneses1, A Téllez1, J Pericàs1, C Falces2, J M Tolosana2, B Vidal2, M Almela3, E Quintana4, J Llopis5, A Moreno1, José M Miro6. 1. Infectious Diseases Service, Hospital Clinic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain. 2. Cardiology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain. 3. Microbiology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain. 4. Cardiovascular Service, Hospital Clinic, University of Barcelona, Barcelona, Spain. 5. Department of Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain. 6. Infectious Diseases Service, Hospital Clinic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain. jmmiro@ub.edu.
Abstract
PURPOSE OF THE REVIEW: Infective endocarditis (IE) is a relatively infrequent infectious disease. It does, however, causes serious morbidity, and its mortality rate has remained unchanged at approximately 25%. Changes in IE risk factors have deeply impacted its epidemiology during recent decades but literature from low-income countries is very scarce. Moreover, prophylaxis guidelines have recently changed and the impact on IE incidence is still unknown. RECENT FINDINGS: In high-income countries, the proportion of IE related to prior rheumatic disease has decreased significantly and has been replaced proportionally by cases related to degenerative valvulopathies, prosthetic valves, and cardiovascular implantable electronic devices. Nosocomial and non-nosocomial-acquired cases have risen, as has the proportion caused by staphylococci, and the median age of patients. In low-income countries, in contrast, rheumatic disease remains the main risk factor, and streptococci the most frequent causative agents. Studies performed to evaluate impact of guidelines changes' have shown contradictory results. The increased complexity of cases in high-income countries has led to the creation of IE teams, involving several specialties. New imaging and microbiological techniques may increase sensitivity for diagnosis and detection of IE cases. In low-income countries, IE remained related to classic risk factors. The consequences of prophylaxis guidelines changes are still undetermined.
PURPOSE OF THE REVIEW: Infective endocarditis (IE) is a relatively infrequent infectious disease. It does, however, causes serious morbidity, and its mortality rate has remained unchanged at approximately 25%. Changes in IE risk factors have deeply impacted its epidemiology during recent decades but literature from low-income countries is very scarce. Moreover, prophylaxis guidelines have recently changed and the impact on IE incidence is still unknown. RECENT FINDINGS: In high-income countries, the proportion of IE related to prior rheumatic disease has decreased significantly and has been replaced proportionally by cases related to degenerative valvulopathies, prosthetic valves, and cardiovascular implantable electronic devices. Nosocomial and non-nosocomial-acquired cases have risen, as has the proportion caused by staphylococci, and the median age of patients. In low-income countries, in contrast, rheumatic disease remains the main risk factor, and streptococci the most frequent causative agents. Studies performed to evaluate impact of guidelines changes' have shown contradictory results. The increased complexity of cases in high-income countries has led to the creation of IE teams, involving several specialties. New imaging and microbiological techniques may increase sensitivity for diagnosis and detection of IE cases. In low-income countries, IE remained related to classic risk factors. The consequences of prophylaxis guidelines changes are still undetermined.
Authors: Daniel C Desimone; Imad M Tleyjeh; Daniel D Correa de Sa; Nandan S Anavekar; Brian D Lahr; Muhammad R Sohail; James M Steckelberg; Walter R Wilson; Larry M Baddour Journal: Circulation Date: 2012-06-11 Impact factor: 29.690
Authors: Christine Selton-Suty; Marie Célard; Vincent Le Moing; Thanh Doco-Lecompte; Catherine Chirouze; Bernard Iung; Christophe Strady; Matthieu Revest; François Vandenesch; Anne Bouvet; François Delahaye; François Alla; Xavier Duval; Bruno Hoen Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Ander Regueiro; Axel Linke; Azeem Latib; Nikolaj Ihlemann; Marina Urena; Thomas Walther; Oliver Husser; Howard C Herrmann; Luis Nombela-Franco; Asim N Cheema; Hervé Le Breton; Stefan Stortecky; Samir Kapadia; Antonio L Bartorelli; Jan Malte Sinning; Ignacio Amat-Santos; Antonio Munoz-Garcia; Stamatios Lerakis; Enrique Gutiérrez-Ibanes; Mohamed Abdel-Wahab; Didier Tchetche; Luca Testa; Helene Eltchaninoff; Ugolino Livi; Juan Carlos Castillo; Hasan Jilaihawi; John G Webb; Marco Barbanti; Susheel Kodali; Fabio S de Brito; Henrique B Ribeiro; Antonio Miceli; Claudia Fiorina; Guglielmo Mario Actis Dato; Francesco Rosato; Vicenç Serra; Jean-Bernard Masson; Harindra C Wijeysundera; Jose A Mangione; Maria-Cristina Ferreira; Valter C Lima; Luiz A Carvalho; Alexandre Abizaid; Marcos A Marino; Vinicius Esteves; Julio C M Andrea; Francesco Giannini; David Messika-Zeitoun; Dominique Himbert; Won-Keun Kim; Costanza Pellegrini; Vincent Auffret; Fabian Nietlispach; Thomas Pilgrim; Eric Durand; John Lisko; Raj R Makkar; Pedro A Lemos; Martin B Leon; Rishi Puri; Alberto San Roman; Alec Vahanian; Lars Søndergaard; Norman Mangner; Josep Rodés-Cabau Journal: JAMA Date: 2016-09-13 Impact factor: 56.272
Authors: Patricia Muñoz; Martha Kestler; Arístides De Alarcon; José María Miro; Javier Bermejo; Hugo Rodríguez-Abella; Maria Carmen Fariñas; Manuel Cobo Belaustegui; Carlos Mestres; Pedro Llinares; Miguel Goenaga; Enrique Navas; José Antonio Oteo; Paola Tarabini; Emilio Bouza Journal: Medicine (Baltimore) Date: 2015-10 Impact factor: 1.817
Authors: Juan M Pericàs; Ruvandhi Nathavitharana; Cristina Garcia-de-la-Mària; Carles Falces; Juan Ambrosioni; Manel Almela; Javier García-González; Eduard Quintana; Francesc Marco; Asunción Moreno; Arnold S Bayer; José M Miró; Adolf W Karchmer Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191
Authors: Laura Herrera-Hidalgo; Arístides de Alarcón; Luis Eduardo López-Cortes; Rafael Luque-Márquez; Luis Fernando López-Cortes; Alicia Gutiérrez-Valencia; María Victoria Gil-Navarro Journal: Antimicrob Agents Chemother Date: 2020-12-16 Impact factor: 5.191